3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Condylomata Acuminata
10
Uterine Cervical Neoplasms
8
Papillomavirus Infections
4
Vulvar Neoplasms
3
Vaginal Neoplasms
3
Uterine Cervical Dysplasia
1
Penile Neoplasms
1
Anus Neoplasms
1
Interventions
GX-188 vaccine
4
human papillomavirus vaccine, L1 type 16, 18
3
Human Papillomavirus DNA Tests
3
Colposcopy
3
Blood Specimen Collection
3
Vaccines
2
VGX-3100
2
Topotecan
2
Restraint, Physical
2
Paclitaxel
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Cisplatin
2
Biopsy
2
5-aminolevulinic acid hexyl ester
2
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
2
terameprocol
1
poly(gamma-glutamic acid)
1
poly ICLC
1
methyl 5-aminolevulinate
1
epigallocatechin gallate
1
artesunic acid
1
artemisinin
1
ZYC101a
1
Watchful Waiting
1
Vaccines, Synthetic
1
Transurethral Resection of Prostate
1
Pregnancy Tests
1
Pemetrexed
1
Papillomavirus Vaccines
1
Ointments
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Cervical Dysplasia
×
Vaccines, Synthetic
×
Clear all
NCT03493542
2024-12-31
V501-213
Merck Sharp & Dohme LLC
Phase 3
Completed
766 enrolled
38 charts